Navigating Market Dynamics: A Deep Dive into Brown Advisory's Investment Decisions

Brown Advisory's Investment Performance and Strategic Shifts in Q2 2026

In the second quarter of 2026, Brown Advisory's Global Leaders Strategy recorded a net return of 4.6%. This performance trailed its benchmark, the MSCI ACWI Net Index, which reported a 14.9% return. The primary factors contributing to this underperformance were reduced exposure to semiconductors and technology hardware, coupled with weaker results in software, cloud services, and financial sector investments. Conversely, the strategy saw positive contributions from investments in AI infrastructure and other AI-related ventures, which benefited from robust market demand. Despite these mixed results, Brown Advisory continues to advocate for active stock selection, noting a significant increase in its 'ready-to-buy' list—the highest since the COVID-19 pandemic. The firm projects an attractive average five-year base-case internal rate of return (IRR) of 12%-13%, emphasizing its commitment to quality, disciplined valuation, and long-term cash flow generation.

Zoetis' Market Position and Recent Performance Challenges

Zoetis Inc. (NYSE:ZTS) stands as a prominent global animal health enterprise, specializing in the development of medications, vaccines, and diagnostic tools for both livestock and companion animals. Despite its robust market position, Zoetis experienced a one-month return of -3.62%, with its share price fluctuating between $71.47 and $160.48 over the past 52 weeks. As of August 7, 2026, the company's stock closed at approximately $77.27 per share, valuing its market capitalization at roughly $30.02 billion. These figures indicate a period of volatility and potential concerns for investors monitoring its trajectory.

The Rationale Behind Exiting Zoetis Investment

Brown Advisory's Global Leaders Strategy made the decision to divest from Zoetis Inc. (NYSE:ZTS) in May, concluding an investment initially driven by Zoetis's leading position as the largest pure-play animal health company. This position offered significant advantages in research and development, alongside unparalleled marketing capabilities to veterinarians and livestock producers, fostering high switching costs. The company's strategic shift towards a more profitable companion animal segment was also a key attraction. However, by 2025, Zoetis began facing increasing growth impediments due to heightened competition in its flagship dermatology and Simparica Trio product lines. Furthermore, the launch of Librela, a novel therapy for canine osteoarthritis pain, did not meet initial performance expectations. The emergence of generic competition in various therapeutic categories further complicated the outlook. Brown Advisory identified three critical concerns: intensified competition within the animal health sector despite high entry barriers; insufficient visibility into Zoetis's future product pipeline to accurately assess its potential contributions; and a misjudgment of Zoetis's defensive capabilities, as it failed to provide the expected portfolio stability during times of deferrable demand. Consequently, the firm concluded that its initial investment thesis for Zoetis was no longer valid, leading to a complete exit from its position.

Exploring Alternative Investment Avenues and Future Outlook

Zoetis Inc. (NYSE:ZTS) is notably absent from our list of the "40 Most Popular Stocks Among Hedge Funds Heading Into 2026." Our analysis indicates a decline in hedge fund interest, with 57 portfolios holding Zoetis Inc. (NYSE:ZTS) at the end of the first quarter, down from 69 in the preceding quarter. While acknowledging the inherent risks and potential of Zoetis as an investment, our firm's current conviction gravitates towards artificial intelligence (AI) stocks, which we believe offer superior potential for higher returns within a condensed timeframe. Investors seeking profoundly undervalued AI stocks that could significantly benefit from future economic trends, such as trade policies and domestic manufacturing shifts, are encouraged to explore specialized reports on the leading short-term AI investment opportunities.